Pharmacological profile and mechanism of action
In modern pharmacology, aripiprazole is considered a prototype of drugs that exert a stabilizing effect on the brain's dopaminergic systems. Unlike classical agents, it acts as a partial agonist of $D_2$ receptors with high affinity for them.
The drug exerts its stabilizing effect through a combined action on two key targets:
- presynaptic receptors (autoreceptors);
- postsynaptic $D_2$ receptors.
Expanded receptor profile
In addition to its effect on the dopamine system, the drug's pharmacodynamics involve serotonin receptors. Aripiprazole exhibits the following properties regarding serotonin receptors:
- Acts as a partial agonist at $5-HT_{1A}$ and $5-HT_{2C}$ receptors.
- Acts as a antagonist at $5-HT_{2A}$.
This complex profile allows the medicinal product to be successfully used in clinical practice for the treatment of severe mental disorders.
Clinical use and safety
The proven efficacy of the drug is confirmed by randomized controlled trial (RCT) results. Aripiprazole is actively prescribed for:
- schizophrenia;
- schizoaffective psychosis.
The main clinical advantage of the therapy is that the drug practically does not cause extrapyramidal symptoms, which favorably distinguishes it from many other neuroleptics.
Briefly: answers to topical questions
What side effects are characteristic of aripiprazole?
- Extrapyramidal symptoms — aripiprazole is associated with a lower risk of parkinsonian symptoms and practically does not cause extrapyramidal disorders.
- Vascular disorders — the drug can act as a trigger for reversible cerebral vasoconstriction syndrome.
Aripiprazole is a "stabilizer-partialist": a partial agonist at D2 and serotonin receptors that keeps the system in balance without excessive shaking or extrapyramidal side effects.
Class and exam questions
What is the main pharmacological action of aripiprazole?
The drug is a partial agonist of D2 receptors with high affinity for them and exerts a stabilizing effect on the dopaminergic system.
Does the drug affect the serotonergic system?
Yes, aripiprazole acts as a partial agonist at 5-HT1A and 5-HT2C receptors, as well as an antagonist at 5-HT2A.
Does aripiprazole cause extrapyramidal symptoms?
No, the drug's safety profile indicates that it practically does not cause extrapyramidal disorders.
What else to study on this topic
- Receptor profile and selectivity of benzamides (using amisulpride as an example)
- Regional and dose-dependent effects in the frontal cortex and limbic system
- The role of presynaptic and postsynaptic receptors in dopamine regulation
- Pathogenetic rationale and the role of the glutamatergic system in schizophrenia
- Promising drugs in clinical trials (bifeprunox and blonanserin)
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Aripiprazole" and 5,304 other pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Agents Used in Psychiatry and Neurology"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.